A round of Series B financing led by Life Sciences Partners has brought in $21 million for Simplify Medical. The proceeds will be used to support two ongoing US trials of the company's Simplify Disc for treating one spinal level, from C3 to C7, and for treating two adjacent spinal levels, from C3 to C7, in patients with cervical degenerative disc disease.
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.